Company profile

Lexicon Pharmaceuticals

Small-molecule therapeutics

LXRX · NASDAQ · USA

Share price · LXRX

$2.42+0.28 (+13.08%) 3M

close as of 2026-08-18 · 24h delayed · vol 2.9M

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Pilavapadin
Phase 3
AP2-associated kinase 1 (AAK1)Small molecule
Diabetic Peripheral Neuropathic Pain
Sotagliflozin (Inpefa)(Inpefa)
Phase 3
SGLT1/2 (dual)Small molecule
Chronic Kidney Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.